Serina Therapeutics, Inc. (SER)

Serina Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-0.94	-11.14	5.27	-2.68	-1.26
Depreciation & Amortization	0.19	0.19	0.09	0.06	0.03
Other Amortization	0.32	0.35	-	-	-
Loss (Gain) From Sale of Assets	-	-	-	0	-0.03
Loss (Gain) From Sale of Investments	-	-	-	0.01	0.01
Stock-Based Compensation	3.5	2.6	0.03	0.01	0.08
Other Operating Activities	-19.55	-5.81	-7.94	0.54	-0.33
Change in Accounts Receivable	-	-	-	0	1.27
Change in Accounts Payable	-1.46	-1.66	0.39	-0	-0.37
Change in Unearned Revenue	0.07	0.07	-	0.15	-1.61
Change in Other Net Operating Assets	-2	-1.72	-0.31	-0.16	-0.05
Operating Cash Flow	-19.88	-17.14	-2.48	-2.08	-2.25
Capital Expenditures	-0.01	-0.02	-0.5	-0.01	-0.08
Investment in Securities	-	-	-	0.99	0.93
Investing Cash Flow	-0.01	-0.02	-0.5	0.98	0.82
Long-Term Debt Issued	-	3.04	10.1	5	-
Long-Term Debt Repaid	-	-0.17	-0.05	-3.69	-0.01
Net Debt Issued (Repaid)	0.49	2.88	10.05	1.31	-0.01
Issuance of Common Stock	10	10	0.02	0	1
Other Financing Activities	4.92	0.34	-	-	-
Financing Cash Flow	15.4	13.21	10.07	1.31	1.08
Net Cash Flow	-4.49	-3.95	7.09	0.22	-0.35
Free Cash Flow	-19.89	-17.16	-2.98	-2.09	-2.34
Free Cash Flow Margin	-39000.00%	-30641.07%	-94.51%	-352.55%	-67.41%
Free Cash Flow Per Share	-2.19	-2.33	-0.41	-0.97	-1.09
Cash Interest Paid	-	-	-	0.02	0
Levered Free Cash Flow	-11.33	-7.94	-0.82	-1.22	-
Unlevered Free Cash Flow	-11.44	-7.96	-0.48	-1.21	-
Change in Net Working Capital	3.17	0.99	-0.87	-0.15	-

Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q